Pre-existing cytotoxic capacity of CD8+and CD4+T cells is a hallmark of richter transformation and favors response to anti-PD-1 therapy
Other conference contribution, 2025
Author
Johan Gustafsson
University of Gothenburg
Massachusetts Institute of Technology (MIT)
Chiara Tomasoni
Cornell University
Graydon Moorhead
Broad Inst Harvard & MIT, Canc Program
Gabriela Brunsting Hoffmann
Dana Farber Canc Inst, Dept Med Oncol
Erik Landolsi
Chalmers, Electrical Engineering, Signal Processing and Biomedical Engineering
Wesley Lu
Dana Farber Canc Inst, Dept Med Oncol
Ruitong Li
Broad Inst Harvard & MIT, Canc Program
Shuqiang Li
Dana Farber Canc Inst, Dept Med Oncol
Dana Farber Canc Inst, Translat Immunogen Lab
Nicholas Haradhvala
Broad Inst Harvard & MIT, Canc Program
Connor Johnson
Broad Inst Harvard & MIT, Canc Program
Stephanie Deng
Dana Farber Canc Inst, Dept Med Oncol
Donna Neuberg
Dana Farber Canc Inst, Dept Data Sci
Xia Bu
Dana Farber Canc Inst, Dept Med Oncol
Gordon Freeman
Dana Farber Canc Inst, Dept Med Oncol
Othman Al-Sawaf
University Hospital Cologne
University of Cologne
Barbara Eichhorst
University Hospital Cologne
University of Cologne
Erin Parry
Dana Farber Canc Inst, Dept Med Oncol
Broad Inst Harvard & MIT, Canc Program
Harvard Medical School
Gad Getz
Broad Inst Harvard & MIT, Canc Program
Massachusetts Gen Hosp, Dept Pathol
Massachusetts Gen Hosp, Krantz Family Ctr Canc Res
Harvard Med Sch, Dept Pathol
Catherine Wu
Dana Farber Canc Inst, Dept Med Oncol
Harvard Medical School
Broad Inst Harvard & MIT, Canc Program
Elisa Ten Hacken
Cornell University
Blood
0006-4971 (ISSN) 1528-0020 (eISSN)
Vol. 146 Suppl 1 243-244Orlando, FL, USA,
Subject Categories (SSIF 2025)
Cell and Molecular Biology
Cancer and Oncology
Immunology in the Medical Area
DOI
10.1182/blood-2025-243